TRENDING:

GBP/USD

XAU/USD

Is Amgen a healthcare stock worth considering? [Video]

Giles Coghlan LLB, Lth, MA Financial Source

Amgen is a multinational biopharmaceutical company that specializes in the development and manufacturing of innovative therapies to treat serious illnesses. The company is focused on using advanced biotechnology and scientific research to address some of the most complex medical conditions, including cancer, cardiovascular disease, kidney disease, inflammatory diseases, and bone disorders.

As a healthcare stock, the company can potentially weather any tougher US financial conditions that may be ahead. This is because even during a recession, healthcare needs are still prioritized, supporting healthcare stocks.

Over the last 20 years, Amgen’s share price has risen 85% of the time between May 31 and July 29, with an average return of 9.14% and an annualized return of over 72%. So, in the face of worries over a looming US recession, is Amgen a healthcare stock worth considering?

Major trade risks: The biggest risk here is if Congress fails to pass the US debt ceiling talks in a timely manner. This could potentially send US stocks into a freefall.

Learn more about HYCM

Author

Giles Coghlan LLB, Lth, MA

Financial Source

Giles is the chief market analyst for Financial Source. His goal is to help you find simple, high-conviction fundamental trade opportunities. He has regular media presentations being featured in National and International Press.

Markets move fast. We move first.

Orange Juice Newsletter brings you expert driven insights - not headlines. Every day on your inbox.

Editor's Picks

EUR/USD trades around 1.1700 after rebounding from 50-day EMA

EUR/USD gains ground after three days of losses, trading around 1.1700 during the Asian hours on Wednesday. On the daily chart, technical analysis indicates a potential for a bearish bias; the 14-day Relative Strength Index at 47 confirms waning momentum.

GBP/USD consolidates around 1.3500; looks to US macro data for fresh impetus

The GBP/USD pair oscillates in a narrow range, around the 1.3500 psychological mark during the Asian session on Wednesday, and for now, seems to have stalled the previous day's retracement slide from its highest level since September 18. Moreover, the fundamental backdrop seems tilted in favor of bullish traders and suggests that the path of least resistance for spot prices is to the upside.

Gold sees profit-taking decline after facing rejection at $4,500

Gold price sees a decline on profit-taking after facing rejection at $4,500 in the Asian trading hours on Wednesday. Despite the pullback, the traditional safe haven remains underpinned by geopolitical tensions and expectations of Fed rate cuts. The US ADP Jobs data, JOLTS Job Openings Survey and ISM Services Purchasing Managers Index report will be published on Wednesday.

Top Crypto Gainers: JasmyCoin rallies as Cosmos and Bittensor retreat

JasmyCoin, Cosmos, and Bittensor are among the top-performing cryptocurrency assets in the last 24 hours. JasmyCoin leads the rally with double-digit gains, and bulls are targeting further gains, while Cosmos and Bittensor struggle to extend their gains after six consecutive days of recovery.

Implications of US intervention in Venezuela

Events in Venezuela are top of mind for market participants, and while developments are associated with an elevated degree of uncertainty, we are not making any changes to our markets or economic forecasts as a result of the deposition of Nicolás Maduro.

Cardano holds steady as bulls intensify push for breakout

Cardano rises above the 50-day EMA resistance amid a risk-on mood across the crypto market. The MACD upholds positive divergence, increasing the potential for a 20% breakout to $0.505.

Legal Text

Markets move fast. We move first.

Editor's Picks

Best Brokers in 2026